Profile data is unavailable for this security.
About the company
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).
- Revenue in USD (TTM)168.77m
- Net income in USD-213.47m
- Incorporated2009
- Employees709.00
- LocationAdaptive Biotechnologies Corp1165 Eastlake Ave ESEATTLE 98109United StatesUSA
- Phone+1 (206) 659-0067
- Fax+1 (206) 659-0667
- Websitehttps://www.adaptivebiotech.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Humacyte Inc | 0.00 | -139.66m | 650.46m | 183.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | -0.237 | 0.00 | -- | -- | 0.00 | -91.17 | -- | -100.75 | -- | -- | -- | -- | -- | -- | -40.08 | -- | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Exscientia PLC (ADR) | 27.92m | -172.15m | 672.13m | 483.00 | -- | 1.68 | -- | 24.07 | -1.35 | -1.35 | 0.2197 | 3.10 | 0.042 | -- | 26.88 | 57,813.92 | -25.87 | -- | -29.52 | -- | -32.45 | -- | -616.50 | -- | -- | -- | 0.0674 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| SS Innovations International Inc | 14.41m | -23.68m | 672.71m | 239.00 | -- | 39.61 | -- | 46.68 | -0.1396 | -0.1396 | 0.0847 | 0.0995 | 0.6003 | 2.28 | 5.08 | 60,293.01 | -98.66 | -161.38 | -216.15 | -449.76 | 28.42 | -79.79 | -164.35 | -495.77 | 0.9128 | -45.39 | 0.4172 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
| MBX Biosciences Inc | 0.00 | -47.20m | 676.25m | 36.00 | -- | -- | -- | -- | -1.48 | -1.48 | 0.00 | 1.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
| Scholar Rock Holding Corp | 0.00 | -203.85m | 681.08m | 150.00 | -- | 5.09 | -- | -- | -2.22 | -2.22 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -79.66 | -38.14 | -89.70 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2726 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| ProKidney Corp | 0.00 | -38.68m | 692.32m | 163.00 | -- | -- | -- | -- | -0.5905 | -0.5905 | 0.00 | -7.73 | 0.00 | -- | -- | 0.00 | -27.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | 67.17 | -- | -- | -- |
| Astria Therapeutics Inc | 0.00 | -93.24m | 696.85m | 59.00 | -- | 2.69 | -- | -- | -2.30 | -2.30 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -32.43 | -64.48 | -33.78 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 20.22m | -109.89m | 701.59m | 201.00 | -- | 1.19 | -- | 34.70 | -2.22 | -2.22 | 0.435 | 11.33 | 0.0416 | -- | -- | 137,544.20 | -22.60 | -32.67 | -23.39 | -34.90 | -- | -- | -543.51 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Adaptive Biotechnologies Corp | 168.77m | -213.47m | 704.92m | 709.00 | -- | 2.92 | -- | 4.18 | -1.47 | -1.47 | 1.16 | 1.64 | 0.2501 | 4.74 | 5.03 | 238,033.80 | -31.65 | -19.69 | -36.63 | -22.06 | 54.77 | 67.18 | -126.55 | -122.27 | 3.84 | -- | 0.3536 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Ironwood Pharmaceuticals, Inc. | 400.57m | 9.21m | 720.42m | 267.00 | 104.37 | -- | 78.13 | 1.80 | 0.0432 | 0.0432 | 2.43 | -2.01 | 0.8021 | -- | 4.52 | 1,500,244.00 | 1.44 | -4.54 | 2.21 | -5.20 | -- | -- | 1.79 | -7.81 | -- | 4.60 | 2.07 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Rapport Therapeutics Inc | -100.00bn | -100.00bn | 740.67m | 58.00 | -- | 2.20 | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
| Wave Life Sciences Ltd | 110.50m | -73.74m | 740.94m | 266.00 | -- | -- | -- | 6.71 | -0.5796 | -0.5796 | 0.9275 | 0.0359 | 0.5036 | -- | -- | 415,413.50 | -33.49 | -56.98 | -117.16 | -102.38 | -- | -- | -66.50 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Annexon Inc | 0.00 | -115.16m | 742.22m | 71.00 | -- | 2.05 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
Data as of Sep 19 2024. Currency figures normalised to Adaptive Biotechnologies Corp's reporting currency: US Dollar USD
74.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Viking Global Investors LPas of 30 Jun 2024 | 29.99m | 20.34% |
| Rubric Capital Management LPas of 30 Jun 2024 | 14.00m | 9.49% |
| Matrix Capital Management Co. LPas of 30 Jun 2024 | 11.57m | 7.85% |
| ARK Investment Management LLCas of 30 Jun 2024 | 11.41m | 7.74% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 10.13m | 6.87% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 9.56m | 6.48% |
| Millennium Management LLCas of 30 Jun 2024 | 9.26m | 6.28% |
| Nikko Asset Management Americas, Inc.as of 30 Jun 2024 | 6.92m | 4.69% |
| Massachusetts Financial Services Co.as of 30 Jun 2024 | 3.91m | 2.65% |
| Aristotle Atlantic Partners LLCas of 30 Jun 2024 | 2.97m | 2.02% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
